QuidelOrtho Corp QDEL
QDEL among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
QDEL and 9 peers, year by year
The 9 Health care companies closest to QDEL in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Gross margin | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|
| QDEL QuidelOrtho Corp | FY2025 | $2.7B | −1.9% | - | −33.7% | −41.5% | −3.0% | −58.9% | 1.40 |
| RPRX Royalty Pharma plc | FY2025 | $2.4B | +5.1% | - | 65.6% | 32.4% | - | 7.9% | 0.92 |
| CHE Chemed Corp | FY2025 | $2.5B | +4.1% | - | 13.4% | 10.5% | 12.9% | 27.1% | - |
| MRNA Moderna | FY2025 | $1.9B | −39.9% | - | −158.1% | −145.2% | −106.2% | −32.6% | 0.07 |
| EXEL Exelixis, Inc. | FY2025 | $2.3B | +7.0% | - | 37.6% | 33.7% | 37.7% | 36.2% | - |
| PRVA Privia Health Group, Inc. | FY2025 | $2.1B | +22.3% | - | 1.6% | 1.1% | - | 3.1% | - |
| RDNT RadNet, Inc. | FY2025 | $2.0B | +11.5% | - | 3.0% | −0.9% | - | −1.7% | 1.00 |
| MEDP Medpace Holdings, Inc. | FY2025 | $2.5B | +20.0% | - | 21.1% | 17.8% | 26.9% | 98.3% | - |
| CON Concentra Group Holdings Parent, Inc. | FY2025 | $2.2B | +13.9% | - | 15.4% | 7.7% | 9.1% | 42.3% | 4.00 |
| HIMS Hims & Hers Health, Inc. | FY2025 | $2.3B | +59.0% | 73.8% | 4.5% | 5.5% | 2.4% | 23.7% | - |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2020 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2020 to FY2025
Revenue as reported in the 10-K.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| QDEL Dec | $1.7B | $1.7B | $3.3B | $3.0B | $2.8B | $2.7B |
| RPRX Dec | $2.1B | $2.3B | $2.2B | $2.4B | $2.3B | $2.4B |
| CHE Dec | $2.1B | $2.1B | $2.1B | $2.3B | $2.4B | $2.5B |
| MRNA Dec | $803.0M | $18.5B | $19.3B | $6.8B | $3.2B | $1.9B |
| EXEL Jan | $987.5M | $1.4B | $1.6B | $1.8B | $2.2B | $2.3B |
| PRVA Dec | $817.1M | $966.2M | $1.4B | $1.7B | $1.7B | $2.1B |
| RDNT Dec | $1.1B | $1.3B | $1.4B | $1.6B | $1.8B | $2.0B |
| MEDP Dec | $925.9M | $1.1B | $1.5B | $1.9B | $2.1B | $2.5B |
| CON Dec | - | - | $1.7B | $1.8B | $1.9B | $2.2B |
| HIMS Dec | $148.8M | $271.9M | $526.9M | $872.0M | $1.5B | $2.3B |
| Peer median | $956.7M | $1.4B | $1.6B | $1.8B | $2.1B | $2.3B |
Sales growth, FY2020 to FY2025
Revenue against the fiscal year before.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| QDEL Dec | - | +2.2% | +92.3% | −8.2% | −7.2% | −1.9% |
| RPRX Dec | +17.0% | +7.9% | −2.3% | +5.2% | −3.9% | +5.1% |
| CHE Dec | +4.2% | −5.5% | −4.7% | +9.4% | +7.4% | +4.1% |
| MRNA Dec | n/m | n/m | +4.3% | −64.4% | −52.7% | −39.9% |
| EXEL Jan | +2.0% | +45.3% | +12.3% | +13.6% | +18.5% | +7.0% |
| PRVA Dec | +3.9% | +18.3% | +40.4% | +22.2% | +4.7% | +22.3% |
| RDNT Dec | −7.1% | +22.7% | +8.7% | +13.0% | +13.2% | +11.5% |
| MEDP Dec | +7.5% | +23.4% | +27.8% | +29.2% | +11.8% | +20.0% |
| CON Dec | - | - | - | +6.6% | +3.4% | +13.9% |
| HIMS Dec | +80.2% | +82.8% | +93.8% | +65.5% | +69.3% | +59.0% |
| Peer median | +4.2% | +22.7% | +10.5% | +13.0% | +7.4% | +11.5% |
Gross margin, FY2020 to FY2025
Gross profit / revenue.
Operating margin, FY2020 to FY2025
Operating income / revenue.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| QDEL Dec | 63.8% | 53.3% | 25.8% | 4.6% | −70.5% | −33.7% |
| RPRX Dec | 75.2% | 62.5% | 13.7% | 63.4% | 57.1% | 65.6% |
| CHE Dec | 18.7% | 16.0% | 16.1% | 15.0% | 15.1% | 13.4% |
| MRNA Dec | −95.0% | 72.0% | 48.9% | −61.9% | −121.9% | −158.1% |
| EXEL Jan | 11.1% | 20.0% | 12.5% | 9.3% | 27.9% | 37.6% |
| PRVA Dec | 3.1% | −22.5% | −1.4% | 1.2% | 1.0% | 1.6% |
| RDNT Dec | 3.3% | 6.3% | 3.2% | 6.1% | 5.7% | 3.0% |
| MEDP Dec | 18.0% | 17.4% | 19.1% | 17.9% | 21.2% | 21.1% |
| CON Dec | - | - | 15.0% | 15.6% | 16.0% | 15.4% |
| HIMS Dec | −10.2% | −42.3% | −13.0% | −3.4% | 4.2% | 4.5% |
| Peer median | 7.2% | 16.7% | 13.7% | 9.3% | 15.1% | 13.4% |
Net margin, FY2020 to FY2025
Net income / revenue.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| QDEL Dec | 48.8% | 41.5% | 16.8% | −0.3% | −73.7% | −41.5% |
| RPRX Dec | 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
| CHE Dec | 15.4% | 12.6% | 11.7% | 12.0% | 12.4% | 10.5% |
| MRNA Dec | −93.0% | 66.1% | 43.4% | −68.8% | −110.0% | −145.2% |
| EXEL Jan | 11.3% | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% |
| PRVA Dec | 3.8% | −19.5% | −0.6% | 1.4% | 0.8% | 1.1% |
| RDNT Dec | −1.4% | 1.9% | 0.7% | 0.2% | 0.2% | −0.9% |
| MEDP Dec | 15.7% | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
| CON Dec | - | - | 9.7% | 9.8% | 8.8% | 7.7% |
| HIMS Dec | −12.2% | −39.6% | −12.5% | −2.7% | 8.5% | 5.5% |
| Peer median | 7.6% | 14.2% | 9.7% | 9.8% | 8.8% | 7.7% |
Free cash flow, FY2020 to FY2025
Cash from operations minus capital spending.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| QDEL Dec | $564.8M | $513.1M | $744.4M | $70.9M | −$112.1M | −$83.0M |
| RPRX Dec | - | - | - | - | - | - |
| CHE Dec | $430.5M | $249.9M | $252.6M | $273.4M | $368.0M | $325.5M |
| MRNA Dec | $2.0B | $13.3B | $4.6B | −$3.8B | −$4.1B | −$2.1B |
| EXEL Jan | $178.6M | $346.6M | $334.9M | $292.9M | $671.5M | $875.8M |
| PRVA Dec | $38.5M | $54.5M | $47.1M | $80.7M | - | - |
| RDNT Dec | - | - | - | - | - | - |
| MEDP Dec | $227.3M | $235.1M | $351.2M | $396.7M | $572.3M | $681.9M |
| CON Dec | - | - | $228.4M | $169.4M | $210.3M | $197.1M |
| HIMS Dec | - | - | −$33.7M | $47.0M | $198.3M | $57.4M |
| Peer median | $227.3M | $249.9M | $252.6M | $169.4M | $289.2M | $261.3M |
FCF margin, FY2020 to FY2025
Free cash flow / revenue.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| QDEL Dec | 34.0% | 30.2% | 22.8% | 2.4% | −4.0% | −3.0% |
| RPRX Dec | - | - | - | - | - | - |
| CHE Dec | 20.7% | 11.7% | 11.8% | 12.1% | 15.1% | 12.9% |
| MRNA Dec | 244.0% | 72.2% | 23.8% | −55.9% | −125.3% | −106.2% |
| EXEL Jan | 18.1% | 24.2% | 20.8% | 16.0% | 31.0% | 37.7% |
| PRVA Dec | 4.7% | 5.6% | 3.5% | 4.9% | - | - |
| RDNT Dec | - | - | - | - | - | - |
| MEDP Dec | 24.6% | 20.6% | 24.1% | 21.0% | 27.1% | 26.9% |
| CON Dec | - | - | 13.2% | 9.2% | 11.1% | 9.1% |
| HIMS Dec | - | - | −6.4% | 5.4% | 13.4% | 2.4% |
| Peer median | 20.7% | 20.6% | 13.2% | 9.2% | 14.3% | 11.0% |
Return on equity, FY2020 to FY2025
Net income / shareholders' equity at the year end.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| QDEL Dec | 60.8% | 36.5% | 11.1% | −0.2% | −68.8% | −58.9% |
| RPRX Dec | 9.9% | 6.0% | 0.4% | 11.3% | 8.3% | 7.9% |
| CHE Dec | 35.4% | 43.1% | 31.3% | 24.6% | 27.0% | 27.1% |
| MRNA Dec | −29.2% | 86.3% | 43.7% | −34.0% | −32.7% | −32.6% |
| EXEL Jan | 5.9% | 10.5% | 7.3% | 9.2% | 23.2% | 36.2% |
| PRVA Dec | 21.3% | −44.1% | −1.7% | 4.1% | 2.3% | 3.1% |
| RDNT Dec | −9.0% | 10.8% | 3.2% | 0.5% | 0.3% | −1.7% |
| MEDP Dec | 18.0% | 19.1% | 63.5% | 50.6% | 49.0% | 98.3% |
| CON Dec | - | - | 17.0% | 15.5% | 60.4% | 42.3% |
| HIMS Dec | n/m | −32.2% | −21.1% | −6.8% | 26.4% | 23.7% |
| Peer median | 9.9% | 10.6% | 7.3% | 9.2% | 23.2% | 23.7% |
Debt / equity, FY2020 to FY2025
Total debt / shareholders' equity at the year end.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| QDEL Dec | - | 0.00 | 0.54 | 0.48 | 0.83 | 1.40 |
| RPRX Dec | 0.59 | 0.69 | 0.75 | 0.61 | 0.74 | 0.92 |
| CHE Dec | - | 0.30 | 0.12 | - | - | - |
| MRNA Dec | - | - | - | - | 0.00 | 0.07 |
| EXEL Jan | - | - | - | - | - | - |
| PRVA Dec | 0.23 | 0.08 | 0.00 | - | - | - |
| RDNT Dec | 3.94 | 3.30 | 2.56 | 1.32 | 1.13 | 1.00 |
| MEDP Dec | - | 0.00 | 0.13 | 0.00 | - | - |
| CON Dec | - | - | - | 0.00 | 5.37 | 4.00 |
| HIMS Dec | n/m | - | - | - | - | - |
| Peer median | 0.59 | 0.30 | 0.13 | 0.31 | 0.93 | 0.96 |
EPS (diluted), FY2020 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| QDEL Dec | $18.60 | $16.43 | $9.56 | −$0.15 | −$30.54 | −$16.69 |
| RPRX Dec | $1.32 | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
| CHE Dec | $19.48 | $16.85 | $16.53 | $17.93 | $19.89 | $18.34 |
| MRNA Dec | −$1.96 | $28.29 | $20.12 | −$12.33 | −$9.28 | −$7.26 |
| EXEL Jan | $0.35 | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |
| PRVA Dec | $0.33 | −$1.83 | −$0.08 | $0.19 | $0.11 | $0.18 |
| RDNT Dec | −$0.29 | $0.46 | $0.17 | $0.05 | $0.04 | −$0.25 |
| MEDP Dec | $3.84 | $4.81 | $7.28 | $8.88 | $12.63 | $15.28 |
| CON Dec | - | - | $1.60 | $1.73 | $1.46 | $1.30 |
| HIMS Dec | −$0.51 | −$0.58 | −$0.32 | −$0.11 | $0.53 | $0.51 |
| Peer median | $0.34 | $1.10 | $0.56 | $0.65 | $1.46 | $1.30 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out QDEL and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: QDEL's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/QDEL/export.csv") into a cell.